AN ARTHRITOGONIC LYMPHOKINE IN THE RAT

BY SIMON M. HELFGOTT, ROSELYNN DYNESIUS-TRENTHAM,
ERNST BRAHN, AND DAVID E. TRENTHAM

From the Department of Medicine, Harvard Medical School, the Department of Rheumatology and Immunology, Brigham and Women's Hospital, and the Division of Rheumatology, Beth Israel Hospital, Boston, Massachusetts 02215

Although substantial evidence suggests that T cells participate in the pathogenesis of rheumatoid arthritis (1), the mechanism(s) involved is unknown. Type II collagen–induced arthritis in rats (2) and mice (3) is an inflammatory synovitis, aspects of which can be passively transferred by immunocompetent cells (4, 5) or IgG antibodies (6-8). The recognition that squirrel monkeys are susceptible to collagen arthritis (9) has created further interest in the potential relevance of this model for human disease. Rats with collagen arthritis develop antigen-specific cellular sensitivity to type II collagen, as measured by in vitro (10-12) and in vivo (13, 14) assays. This paper reports the identification and partial physicochemical characterization of a type II collagen–induced lymphokine that is arthritogenic in rats.

Materials and Methods

Animals. 100–125-g rats from the following inbred strains were used in separate experiments: female Wistar-Furth (W-F) (Microbiological Associates, Walkersville, MD); female Louvain-MN (LOU-M) and LOU-C of either sex (Small Animal Facility, National Institutes of Health, Bethesda, MD); and female Listar (LIS) from a colony maintained at the Animal Resource Center of Harvard Medical School (Boston, MA). Histocompatibility in all strains was verified using mixed lymphocyte culture techniques (4, 15). Male DBA/2 mice weighing 25–30 g were purchased from the Jackson Laboratory (Bar Harbor, ME).

Collagen. Type II collagen, prepared by pepsin treatment of lathyritic chick sternal cartilage by a method previously described (2, 13), was either obtained from a commercial source (Genzyme Corp., Boston, MA) or purified in our laboratory. Type I collagen had been previously prepared (16), using pepsin, from the skin of lathyritic chicks. Collagens were tested for purity by amino acid analysis and disc sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE)1 (17). Except for the portions of type II collagen that were thermally denatured (2), preparations were in the native state.

Sensitization. Sensitization was achieved by injecting rats intradermally with 0.4 mg of

1 Abbreviations used in this paper: AF, arthritogenic factor; BS, Blue-Sepharose; Con A, concanavalin A; DFP, diisopropylphosphofluoridate; IL, interleukin; LIF, leukocyte inhibitory factor; LNC, lymph node cells; OD, optical density; PG, prostaglandin; PHA, phytohemagglutinin; SDS-PAGE, sodium dodecyl sulfate–polyacrylamide gel electrophoresis.
collagen solubilized in 0.5 ml 0.1 M acetic acid, and emulsified in 0.5 ml incomplete Freund's adjuvant (2), or 0.25 mg ovalbumin (grade V; Sigma Chemical Co., St. Louis, MO) solubilized in 0.5 ml 0.9% NaCl and emulsified in 0.5 ml complete Freund's adjuvant (12). To stimulate lymph node hypertrophy for experiments requiring nonsensitized cells, rats were injected intradermally with 0.5 ml of 0.9% NaCl emulsified in 0.5 ml of incomplete Freund's adjuvant (12).

**Cell Preparation.** Lymph node cells (LNC) were obtained at sacrifice 14–21 d after antigen injection, and subjected to Ficoll-Hypaque centrifugation to facilitate removal of nonviable cells (12). Nylon wool–passaged LNC and plastic-adherent LNC (17) were used as sources of T cell–enriched and monocyte/macrophage–enriched populations, respectively. <1.5% of the nylon wool-eluted population showed positive staining using a fluorescein-conjugated goat anti-rat gamma globulin (E.Y. Pharmaceuticals, San Mateo, CA) (18), whereas >95% of the plastic-adherent cells were positive by esterase staining (17). Type II collagen–coupled spleen cells, which are capable of inducing antigen-specific delayed hypersensitivity when injected subcutaneously, were prepared using ethylcarbo-
diimide (16).

**Cultures.** LNC were cultured in Corning 25200 tubes (Corning Glass Works, Corning, NY) at a density of 10^7 cells/ml in medium 199 (Microbiological Associates), supplemented with penicillin-streptomycin (100 U and 100 μg/ml, respectively), buffered with 20 mM Hepes solution (Gibco Laboratories, Grand Island, NY), and made to contain 2% heat-inactivated fetal calf serum (Lot 3656; IBL Tissue Culture Products, Rockville, MD), for 48 h at 37 °C in a humidified atmosphere containing 95% air and 5% CO_2 in the presence or absence of concentrations of concanavalin A (Con A), phytohemagglutinin-M (PHA), or antigen found to be optimal for the generation of rat leukocyte inhibitory factor (LIF) (12). T cell– and monocyte-enriched populations were cultured under these conditions at densities of 10^7 and 10^5 cells/ml, respectively. Cell viability (12) exceeded 95% at culture onset. After 48 h, supernatants were pooled, clarified by centrifugation (12,000 g for 20 min), dialyzed at 4 °C against 0.9% NaCl and water for an additional 48 h, and concentrated to a volume of ~1.0 ml per 10^9 cells by vacuum dialysis or lyophilization. Vacuum-dialyzed material was tested immediately, and lyophilized material was stored at −20°C (12).

**Establishment of Antigen-reactive T Cell Lines.** T cell lines were established using the method of Ben-Nun et al. (19). LOU-M or -C LNC were obtained 7–10 d postimmuniza-
tion with type II collagen or ovalbumin and suspended at a density of 5 × 10^6 cells/ml in Dulbecco's modified Eagle's medium (Microbiological Associates), supplemented with 10% fresh rat serum, 2-mercaptoethanol (5 × 10^-5 M), penicillin-streptomycin, and Hepes. LNC were cultured in 100-mm petri dishes (6 ml/dish) with antigen (12). After 72 h of incubation, the cells were harvested and the lymphoblasts separated by centrifugation using a discontinuous Ficoll gradient (19). A fraction containing >90% lymphoblasts was found consistently in the interface between densities of 1.06 and 1.05 g/ml. These cells were recovered by pipetting, washed twice, and cultured at a density of 2 × 10^5 cells/ml in Dulbecco's modified Eagle's medium supplemented with 20% (vol/vol) of supernatant containing interleukin 2 (IL-2), 10% horse serum (Gibco Laboratories), 2-mercaptoethanol, nonessential amino acids, sodium pyruvate, antibiotics, and Hepes, without added antigen (10 μg/ml) (20). The IL-2-containing supernatant was prepared using Con A–stimulated DBA/2 spleenocytes (20). The isolated lymphoblasts that were propagated represented ~1% of the starting LNC population.

After 7 d, cells undergoing further selection were harvested and resuspended in the culture medium at a density of 2 × 10^6 cells/ml together with 10^7 cells/ml irradiated (1,500 rad) syngeneic accessory cells (from the spleen of naive rats) and antigen (collagen or ovalbumin). After 72 h of incubation, the cells were collected, washed, and applied to a Ficoll-Hypaque gradient to isolate the viable lymphoblasts (12). The lymphoblasts were resuspended in propagation culture medium (2 × 10^5 cells/ml) and reseeded (10 ml/dish). After 3–4 d of incubation, the cells were harvested and restimulated with antigen as described above. Supernatants used in this study were collected on either day 20 or 56, which was at the end of an antigen-stimulation cycle. T cell membrane markers were
identified as described (18), using the murine monoclonals, W3/13, W3/25, and OX8 (Accurate Chemical and Scientific Corp., Westbury, NY) and fluorescein-conjugated F(ab')2 fragments of goat anti-mouse IgG (Fc fragment-specific) (Cappel Laboratories, Cochranville, PA).

**Thymidine Incorporation Assay.** Proliferation responses of line cells to Con A and antigen stimulation were measured by a thymidine incorporation technique adapted from one used previously (10, 13). Line cells were incubated in round-bottomed microtiter plates in quadruplicate wells. Each well contained 2.5 × 10⁴ cells plus 10⁵ accessory cells consisting of irradiated (1,500 rad) syngeneic spleen cells in 0.2 ml Dulbecco’s modified Eagle’s medium with 1% fresh rat serum in the presence or absence of antigen/mitogen at described concentrations (12, 13). After 48 h of incubation, cells in each well were pulsed with 1 μCi [³H]thymidine (sp act, 5.0 Ci/mM; Amersham Corp., Arlington Heights, IL), and incorporation was measured 18 h later (21). Results are expressed as a stimulation index, calculated as (mean cpm with antigen or Con A)/(mean cpm without antigen or mitogen).

**Gel Filtration.** Lyophilized supernatant material was fractionated on a calibrated column (2.5 × 100 cm) containing Sephadex G-100 (Pharmacia Fine Chemicals, Piscataway, NJ) and was subsequently processed as described (12).

**Affinity Chromatography.** Supernatant material, derived from serum-containing cultures of nylon wool-purified cells or line cells, was depleted of albumin using the method of Travis et al. (22). 40 mg of lyophilized crude supernatant material was solubilized in 0.05 M Tris-HCl with 0.1 M KCl, pH 7.0, and applied to a preequilibrated 0.9 × 30 cm column containing Blue-Sepharose CL-6B (BS) (Pharmacia Fine Chemicals). Fractions of unbound material with an optical density at 280 nm (OD280) of >0.05 were pooled (BS peak I). Bound material, including albumin, was eluted with 0.05 M Tris-HCl and 0.2 M NaSCN, pH 8.0 (BS peak II). Both pools were vacuum dialyzed to about one twentieth their original volume. Depletion efficiency was assessed by radial immunodiffusion, using 1.5% agarose containing a 1:50 dilution of rabbit anti-horse albumin (Cappel Laboratories) or rabbit anti-bovine albumin (Cappel Laboratories), where appropriate. Up to 96% of the albumin was removed from BS peak I by this procedure.

For the final affinity isolation, collagen was linked to CNBr-activated Sepharose 4 B (Pharmacia Fine Chemicals), using the method of Stuart et al. (6). Once the ligand (type I or II collagen) had been bound and the gel reequilibrated with the coupling buffer (0.01 M phosphate-buffered saline with 0.5 M NaCl), 4 ml of BS peak I in phosphate-buffered saline was added to the gel and incubated overnight at 4°C with rocking. A 1 × 6 cm column was filled with the gel, washed with phosphate-buffered saline until the OD280 was <0.01, and fractions were pooled (CNBr peak I). A 0.2 M glycine-HCl wash, pH 2.8, was pumped onto the column and allowed to remain for 3 h before eluting. These latter fractions were also pooled (CNBr peak II). Elution profiles were monitored at OD280 and concentrations determined by the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA), with bovine serum albumin as a standard (23). Both pools were dialyzed for 48 h against distilled water, lyophilized, and stored at −20°C.

**SDS-PAGE.** Discontinuous SDS-PAGE was performed as described by Laemmli (24). All samples were run under reduced conditions using 2-mercaptoethanol. 10% polyacrylamide, 1.5-mm-thick slab gels were stained by a silver nitrate method, which detects quantities of protein of ≥10 ng (25). Relative molecular weight (Mr) was determined using the following Bio-Rad protein standards: phosphorylase b (92,500), bovine serum albumin (66,200), ovalbumin (50,000 and 45,000), carbonic anhydrase (31,000), and soybean trypsin inhibitor (21,500).

**Immunoglobulin Preparation.** Material enriched for Ig was prepared by ammonium sulfate precipitation (16) of pooled serum, obtained at sacrifice from the rats that developed collagen arthritis, or from immunologically naive rats, and stored at −20°C. The IgG antibody titer to native type II collagen was measured by an enzyme-linked immunosorbent assay (26).

**Intraarticular Injections.** Crude or G-100-fractionated supernatant and Ig-enriched material were resuspended in Hanks’ balanced salt solution (Microbiological Associates)
1534 AN ARTHRITGENIC LYMPHOKINE IN THE RAT

at a ratio of 1:1 (vol/vol). Protein concentrations of the crude supernatants were ~700 mg-percent, as measured by the Lowry technique (27). Affinity-purified supernatant material was resuspended in Hanks' balanced salt solution at a concentration of ≤10 mg-percent protein. Suspensions were membrane (0.45 μm)-sterilized. Under aseptic conditions, 200 μl of the crude or G-100 suspension was injected through the avascular region of the infrapatellar ligament (28) into one knee of a syngeneic naive rat, lightly anesthetized with ether, using a 26-gauge needle. For affinity-purified supernatants, 100 μl was injected.

Arthritis Assessments. After knee injection, rats were evaluated at least every other day for overt clinical signs of arthritis, i.e., a limping gait or obvious knee-joint swelling. Unless specified, rats were sacrificed 7 d postinjection. Synovial tissue overlying the infrapatellar fat pad and the contiguous margins of the patellar and/or tibial cartilage were removed and blocked in paraffin; multiple 5-7-μm-thick sections were obtained and either stained with hematoxylin and eosin, or processed for immunofluorescence (28). Based upon morphologic studies in collagen arthritis (2, 4, 28, 29), and a method used by Andreis et al. (30) in a rabbit-synovitis model, a scoring system was devised for the hematoxylin and eosin-stained slides to reflect (a) the magnitude of diffuse synovial membrane thickening (<5 cell layers thick = 0; 5-10 cell layers = 1; 10-15 cell layers = 2; >15 cell layers = 3), and (b) the degree of inflammatory cell (mononuclear cells and polymorphonuclear leukocytes) infiltration and neovascularization in the subsynovial layers (absent = 0; minimal = 1; moderate = 2; marked = 3). Each of the two categories was assigned an integer, resulting in a maximum histologic score of six. Slides were read by the same observer, who was unaware of the experimental group from which the tissue had been obtained; at least five sections were evaluated from each knee.

Physicochemical Treatments. G-100-fractionated supernatant material was exposed to heat, chymotrypsin (a proteinase with broad specificities), and to the serine esterase inhibitor, diisopropylphosphofluoridate (DFP) under conditions previously used to characterize rat LIF (12). In other experiments, LNC from arthritic rats were cultured in the presence or absence of the endotoxin inactivator, polymyxin B (5 μg/ml) (17), or puromycin, which was used at a nonlethal concentration to block de novo protein synthesis, and removed by methods already described (12).

LIF Assay. LIF activity in G-100-fractionated material was measured by its ability to inhibit the migration of rat polymorphonuclear leukocytes from capillary tubes. Activity generated by Con A provided a control (12).

Complement Depletion. Cobra venom factor was prepared and analyzed by the method of Salant et al. (31). Rats were injected intraperitoneally with 75 and 25 U (32) cobra venom factor on day -1 and day 4, respectively, and intraarticularly with G-100-fractionated material on day 0. Serum C3, measured by Mancini single radial immunodiffusion (33), was undetectable in all of the rats on day 4, and was <45% of the pretreatment value on day 7, when the rats were sacrificed.

Statistical Analyses. Continuous variables were analyzed by their group means (Student’s t-test) and dichotomous variables by their proportionate group frequencies (χ² test).

Results

Identification of Arthritogenic Factor (AF). As shown in Table I, a significant synovitis developed in the injected knees of W-F rats receiving the crude supernatant material from cultures of LNC or T cells from collagen-arthritic rats stimulated in vitro with native type II collagen. Although ovalbumin is a potent cellular immunogen in rats (12, 16), injection of supernatants derived from ovalbumin-sensitized LNC did not create this lesion. Only minimal inflammation developed following injection of Ig containing antibodies to type II collagen. The inability of collagen-coupled cells, as well as supernatants derived by culturing LNC from nonarthritic cells or macrophage-enriched cell populations with native type II collagen, to induce appreciable synovitis suggests that collagen carryover does not explain the results of these experiments.
Table I

Histologic Assessment of Synovial and Subsynovial Tissue in Knees from W-F Rats Injected with Crude Supernatant or Serum-derived Material

| Antigen          | Donor* | Cell Stimulus | Material Injected | Histologic Score (x SEM) | P     |
|------------------|--------|---------------|-------------------|--------------------------|-------|
| Type II          | Arthritic | Type II LCNC | Supernatant       | 3.9 ± 0.5 (14)†         | —     |
| Type II          | Arthritic | Denatured Type II LCNC | Supernatant       | 2.0 ± 0.6 (8)           | 0.03† |
| Type II          | Nonarthritic | Type II LCNC | Supernatant       | 1.6 ± 0.3 (10)          | 0.002† |
| Type I           | Nonarthritic | Type I LCNC | Supernatant       | 1.7 ± 0.3 (10)          | 0.003† |
| Type II          | Arthritic | LCNC Con A    | Supernatant       | 0.7 ± 0.7 (7)           | 0.003† |
| Type II          | Arthritic | LCNC PHA      | Supernatant       | 1.5 ± 0.5 (4)           | 0.03† |
| Type II          | Arthritic | T cell        | Supernatant**     | 3.5 ± 0.6 (6)†          | —     |
| Type II          | Nonarthritic | Ovalbumin | Supernatant**     | 1.5 ± 0.3 (4)           | 0.03† |
| Type II          | Arthritic | Macrophage    | Supernatant††      | 1.2 ± 0.5 (4)           | 0.09† |
| Type II          | Arthritic | Type II LCNC | Type II-coupled cells | 1.5 ± 0.5 (4)           | 0.03† |
| Type II          | Arthritic | Type II LCNC | Arthritic serum fraction | 2.1 ± 0.4 (8)           | 0.03† |
| Type II          | Arthritic | Type II LCNC | Nonarthritic serum fraction | 2.0 ± 0.5 (6)           | 0.03† |
| Type II          | Arthritic | Type II LCNC | Nonimmune serum fraction | 1.2 ± 0.6 (5)           | 0.01† |
| Type II          | Arthritic | Type II LCNC | Hanks' balanced salt solution | 0.4 ± 0.4 (5)           | 0.001† |

* 70% of the rats developed arthritis 10–16 d after immunization with native type II collagen. In these and previous experiments (2, 10), no arthritis resulted when rats were immunized with the other antigens.

† Significance compared to score produced by supernatant from the arthritic LNC cultured with type II collagen.

‡ Histologic scores are given as mean ± SEM for each group.

§ One rat developed limping and swelling of the knee.

‖ One rat developed limping and swelling of the knee.

** Knees received material derived from 10⁸ nylon wool-purified cells.

---

To estimate the molecular mass of the lymphokine responsible for this inflammatory activity, lyophilized material from arthritic W-F LNC cultured with type II collagen underwent Sephadex G-100 filtration. The eluate from 10 columns was divided into three fractions (high molecular mass fraction, 90–60 kilodaltons [kD]; intermediate fraction, 60–23 kD; and low molecular mass fraction, <23 kD). 9 (41%) of 22 rats injected with the high fraction, vs. 1 of 15 rats injected with the intermediate fraction, and none of 18 rats injected with the low molecular mass fraction developed overt clinical signs of knee arthritis (P < 0.01 for both comparisons) (Fig. 1). The mean histologic score of rats injected with the high-mass fraction was significantly greater than the scores of the other two groups (Table II). Additional subfractionation of G-100-derived material indicated that AF activity eluted in the 60–70 kD range. Other studies depicted in Table II showed that AF was an in vitro-synthesized protein, distinct from the similarly sized lymphokine, LIF (12), and not inactivated at 56°C; its arthritogenicity was not likely to be due to contamination by endotoxin. Complement depletion with cobra venom factor did not affect the response of rats to AF.

Affinity Purification of AF. The inability of mitogens and antigens other than native type II collagen to generate arthritogenic supernatants (Table I) suggested that AF is an antigen-specific lymphokine. Accordingly, W3/25+ T cell lines were established from collagen-immunized LOU-M and LOU-C rats that reacted
specifically to type II collagen (Table III). The LOU strain was selected because of its high degree of susceptibility to collagen arthritis observed in other (unpublished) studies. An additional W3/25* line was established from LOU-M rats immunized with ovalbumin and CFA by stimulation with ovalbumin; this line reacted to antigenic challenge with both ovalbumin and mycobacteria.

The supernatant materials derived from these cell lines were used in the following affinity chromatography studies. The two collagen-reactive T cell lines produced material that bound to type II collagen, and when eluted, gave pronounced AF responses in the knee assay (Table IV). This antigen-binding AF activity was also generated by nylon wool–nonadherent cells obtained from arthritic W-F and LIS rats. No binding occurred when this material was passaged through an affinity column prepared with type I collagen. The ovalbumin/mycobacteria–reactive line did not produce collagen-binding AF activity. Material enriched for lymphokines by stimulating naive nylon wool–nonadherent cells with Con A and subjecting the supernatant to attempted affinity purification on the type II collagen column was also devoid of AF activity. This result, as well as the outcome of the ovalbumin/mycobacteria line experiment, make it unlikely that collagen leached off the affinity column produced the inflammation in these studies.

SDS-PAGE under reducing conditions showed a single protein band in the T cell–derived AF containing materials eluting from the type II collagen–Sepharose column (Fig. 2). Similar to the molecular mass estimates by gel filtration, the

Figure 1. Swollen knee (viewer’s right) 7 d after injection of G-100-enriched AF, compared to the uninjected knee, of a sacrificed rat in which the overlying skin has been reflected.
## Table II

**Studies of Rat AF in W-F Rats**

| Material tested | Histologic score (n) | p   |
|-----------------|----------------------|-----|
| Fractionated AF (kD) |                      |     |
| 60–90           | 3.8 ± 0.5 (22)*      |     |
| 23–60           | 1.8 ± 0.4 (15)      | 0.01|
| <23             | 1.1 ± 0.2 (18)      |     |
| 60–70           | 2.8 ± 0.3 (11)      |     |
| 50–60           | 2.0 ± 0.4 (8)       | NS  |
| 70–80           | 1.0 ± 0.3 (11)      | 0.001|
| 80–90           | 0.7 ± 0.3 (11)      | 0.001|
| Normal recipient | 2.9 ± 0.5 (7)       |     |
| Complement-depleted recipient | 2.8 ± 0.8 (4) | NS  |
| Incubation without chymotrypsin | 2.9 ± 0.5 (7) |     |
| Incubation with chymotrypsin | 0.7 ± 0.3 (3) | 0.02|
| Incubation without DFP | 2.0 ± 1.0 (2) |     |
| Incubation with DFP† | 2.0 ± 0.0 (2) | NS  |
| No heat         | 2.2 ± 0.5 (4)       |     |
| Heat (56°C, 30 min) | 2.0 ± 0.6 (5) | NS  |
| Heat (80°C, 30 min) | 0.6 ± 0.6 (5) | NS  |
| Unfractionated material‡ | 3.9 ± 0.5 (14)‡ |     |
| Polymyxin B    | 3.5 ± 0.6 (4)       | NS  |
| Puromycin      | 1.7 ± 0.5 (4)       | 0.05|

Designations are identical to those described in Table I.

* Nine rats developed limping and swelling of the knee.

† Obtained by culturing arthritic LNC with type II collagen in the presence or absence of a drug.

NS, not significant.

The resistance of AF to DFP indicates that, unlike rat LIF, this protein is not a serine esterase (12). In addition, this fractionated AF preparation did not possess LIF activity (mean migration inhibition was 8% vs. 54% for AF and Con A–induced LIF, respectively).

Characteristics of Lesion Induced by AF. Pannus formation, neovascularization, and synovial infiltrates, consisting predominantly of mononuclear inflammatory cells, some polymorphonuclear leukocytes, and a few eosinophils, were found as early as 48 h after injection of G-100-enriched AF into the knees of W-F rats. Cartilage erosion was also noted at this time (Fig. 3). Granulomatous areas were occasionally observed in the pannus of day 7 lesions induced with G-100-enriched AF, and immunofluorescence evaluation of synovia during the period 2–7 d
TABLE III
Thymidine Incorporation Responses by T Cell Lines

| Strain | Propagating antigen | Background (cpm) | Stimulation index with antigen or mitogen |
|--------|---------------------|-----------------|------------------------------------------|
|        |                     |                 | Type II | Type I | Ovalbumin | PPD* | Mycobacteria | Con A |
| LOU-M  | Type II             | 398 ± 97        | 16.8    | 0.7    | 0.8       | 0.4  | ND           | 7.8   |
| LOU-C  | Type II             | 199 ± 16        | 1.5     | ND     | ND        | 0.9  | ND           | 1.3   |
| LOU-M  | Ovalbumin           | 15,772 ± 830x   | 1.1     | ND     | 2.4       | 1.2  | 2.0          | 3.6   |

Measured in quadruplicate by 3-d cultures of aliquots of 2.5 × 10^5 line cells and 10^6 syngeneic accessory cells, obtained from the spleen and irradiated with 1,500 rad. The cells were cultured in the presence of 10 μg/ml of antigen or mitogen and 1% fresh autologous serum. Line cells were tested for [3H]thymidine incorporation 17 d after onset of primary culture, and showed 95-98% staining positivity for the W3/25 antigen at this time. ND, not done.

* PPD, purified protein derivative of tuberculin.

This high degree of proliferation in the resting state is similar to that observed (47, 48), on occasion, in other established rat T cell lines.

TABLE IV
Assessment of Knees Injected with Cell-derived Material Tested for Ability to Bind Type II Collagen

| Antigen | Donor | Strain | Culture | Affinity column | Histologic score (n) | P |
|---------|-------|--------|---------|-----------------|-----------------------|---|
| Type II | Arthritic | W-F | T | Type II | Type II | 4.1 ± 0.3 (5) | 0.001 |
| Type II | Arthritic | LIS | T | Type II | Type II | 4.1 ± 0.3 (4) | 0.003 |
| Type II | Prearthritic | LOU-M | T line | Type II | Type II | 4.3 ± 0.4 (6) | 0.001 |
| Type II | Prearthritic | LOU-C | T line | Type II | Type II | 3.6 ± 0.2 (6) | 0.001 |
| Type II | Arthritic | W-F | T | Type II | Type II | 1.6 ± 0.5 (5) | NS |
| Ovalbumin | Nonarthritic | LOU-M | T line | Ovalbumin | Type II | 1.4 ± 0.4 (6) | NS |
| — | Naive | W-F | T | Con A | Type II | 1.0 ± 0.6 (6) | — |

Designations are identical to those described in Tables I and II.

* Cell culture represents either nylon wool-purified T cells or an aliquot of cells from a T cell line obtained 17 (LOU-M) or 53 d (LOU-C) after the onset of culture.

† Derived from tissue samples 7 d after injection of 100 μl of glycine-HCl eluate from the native collagen-Sepharose column. Protein concentrations in the eluates were ≤ 0.1 mg/ml.

postinjection detected abundant fibrin, and rare deposits of Ig and complement (C3). Histologically, the synovitis induced in the knees of LOU rats by the affinity-purified AF was similar to that observed using G-100-enriched material (Fig. 4). Four knees of LOU-M rats injected 25 d earlier with affinity-purified, line cell–derived AF showed hyperplasia of the synovial lining, mononuclear cell infiltration, subsynovial fibrosis, and occasional granulomas (mean histologic score ± SE, 3.6 ± 0.3).

Discussion

These data demonstrate the existence of AF, a novel T cell–derived arthritogenic lymphokine, in different strains of rats. At least a portion of this arthritogenic activity is antigen binding, and the ability of native type II collagen to affinity purify AF activity suggests that the responsible species is an antigen-
specific lymphokine reactive with epitopes on type II collagen. The ability of puromycin to block the generation of AF activity in vitro indicates that the protein is not preformed. Further analytic and functional characterization of AF is required to ascertain with greater certainty whether or not AF exists solely as a single 65 kD polypeptide in the rat. Additional work is also necessary to determine whether the bioactivity of AF crosses strains and/or species, or is major histocompatibility complex-restricted.

Most studies of antigen-specific T cell–derived factors have identified those with suppressor properties (34, 35), however, analogous factors with promoting activities have been detected in several murine systems (36–38). The ability of native, but not denatured, type II collagen to stimulate degrees of AF activity that are readily detectable by bioassay suggests that rat T cells capable of recognizing quarternary epitopes on collagen exist. Previous studies in collagen arthritis have provided additional indirect evidence supporting this proposal (10, 16). Murine T cells reactive with conformationally dependent determinants on insulin have been identified recently by Glimcher et al. (39), providing precedence for such a phenomenon.

Although the collagen-reactive LOU-M and LOU-C T cell lines differed
markedly in their ability to respond in vitro to native type II collagen by thymidine incorporation, both lines generated statistically similar degrees of AF activity. This finding provides evidence that the capacity to proliferate and produce lymphokines in response to antigen stimulation by various T cell lines is dissociable, although the basis for this phenomenon is unclear.

The molecular mass of AF differs from the ~20 kD protein, catabolin (40), which stimulates chondrocytes in vitro, nor is AF identical to the ~15 kD collagen-inducible cytokine, IL-1 or mononuclear cell factor, which heightens release of collagenase and prostaglandin E2 (PGE2) by cultured human synovial cells (17) and mediates cartilage matrix degradation (41). A substance, functionally equivalent to mononuclear cell factor in the synoviocyte assay, can be generated in rats by stimulating naive LNC with Con A, but its Mr by G-100 filtration is 10,000–20,000 (C. E. Brinckerhoff and D. E. Trentham, unpublished data). Another difference from mononuclear cell factor is the inability of G-100 fractionated AF to stimulate release of collagenase and PGE2 in the in vitro rat synoviocyte system (C. E. Brinckerhoff, S. M. Helfgott, and D. E. Trentham, unpublished data).

In rats, the erosive joint lesion that results from intravenous injection of affinity-purified collagen antibodies has been reported (8) to be complement-dependent, and to consist largely of polymorphonuclear leukocyte infiltration, rather than pannus formation. The apparent lack of involvement of blood complement and the mononuclear inflammatory cell preponderance in the AF-
FIGURE 4. (a) A hypertrophied and inflamed synovium induced by injecting (7 d earlier) ~10 µg of affinity-purified AF, generated by the type II collagen-specific LOU-M T cell line, vs. (b) a normal rat knee synovium. (Original magnification, × 400).
induced lesion make it unlikely that antibody production by the recipient accounts for the arthritogenic effect of AF.

Although the initiation of collagen arthritis has been postulated (6, 7) to be an antibody-mediated event, the lesion produced by antibody is transient (6–8), and is incapable of being sustained by repeated injections (42). In contrast, a persistent arthritis characterized by extensive synovial hypertrophy can be induced by the intravenous injection of collagen-sensitized spleen cells and LNC in rats (4), or by injection of nylon wool–purified T cells in mice (5). In the recipients of cells, no serum antibody response to collagen was detected (4, 5). These passive transfer experiments may indicate that cellular immunity plays a major role in the pathogenesis of collagen arthritis. The recognition of AF identifies a mechanism whereby this process could be subserved.

Increasing attention is being directed to the role of T cells in the pathogenesis of rheumatoid arthritis (1). Lymphokine-like moieties have been identified in the synovial fluid of patients with this disease (43). An inflammatory synovitis of the knee can be induced in rabbits by repeated intraarticular injections of culture supernatants containing factors generated by homologous LNC sensitized to keyhole limpet hemocyanin (30). The identification of AF in an animal model, and the presence of cellular sensitivity to collagen in patients with rheumatoid arthritis (44–46) are consistent with the hypothesis that this lymphokine is an effector molecule in human synovial disease.

Summary

A type II collagen–specific arthritogenic lymphokine has been identified in the rat. Arthritogenic factor (AF) is a 65 kD protein generated in vitro by T cells from rats with collagen arthritis, and it induces an erosive, proliferative synovitis when injected into the knee joint of syngeneic naive recipients. Complement does not appear to be required. These data identify a potential T cell–mediated effector mechanism in this model, and suggest that AF may function in other inflammatory synovial diseases.

We thank D. Rowland for technical assistance, L. Oligino, D. Harn, and J. Wilson for their advice, C. Sledge for use of his research facilities, and J. Miccile and D. Condon for manuscript preparation.

Received for publication 15 May 1985 and in revised form 14 August 1985.

References

1. Trentham, D. E. 1984. Strategies for medical treatment based on current understanding of the pathogenesis of rheumatoid arthritis. Clin. Orthop. Relat. Res. 182:31.
2. Trentham, D. E., A. S. Townes, and A. H. Kang. 1977. Autoimmunity to type II collagen: an experimental model of arthritis. J. Exp. Med. 146:857.
3. Courtenay, J. S., M. J. Dallman, A. B. Dayan, A. Martin, and B. Mosedale. 1980. Immunisation against heterologous type II collagen induces arthritis in mice. Nature (Lond.). 283:666.
4. Trentham, D. E., R. A. Dynesius, and J. R. David. 1978. Passive transfer by cells of type II collagen–induced arthritis in rats. J. Clin. Invest. 62:359.
5. Blum Stampfer, C., and D. E. Trentham. 1985. Adoptive transfer of collagen arthritis in mice by lymphoid cells. Fed. Proc. 44:1179a (Abstr.).
6. Stuart, J. M., M. A. Cremer, A. S. Townes, and A. H. Kang. 1982. Type II collagen-induced arthritis in rats: passive transfer with serum and evidence that IgG anticollegen antibodies can cause arthritis. J. Exp. Med. 155:1.
7. Stuart, J. M., and F. J. Dixon. 1983. Serum transfer of collagen-induced arthritis in mice. J. Exp. Med. 158:378.
8. Kerwar, S. S., M. E. Englert, R. A. McReynolds, M. J. Landes, J. M. Lloyd, A. L. Oronsky, and F. J. Wilson. 1983. Type II collagen-induced arthritis: studies with purified anticollagen immunoglobulin. Arthritis Rheum. 26:1120.
9. Cathcart, E. S., K. C. Hayes, S. Gonneman, A. A. Lazzari, and C. Franzblau. 1984. Experimental arthritis in a nonhuman primate. Clin. Res. 32:462a (Abstr.).
10. Trentham, D. E., A. S. Townes, A. H. Kang, and J. R. David. 1978. Humoral and cellular sensitivity to collagen in type II collagen-induced arthritis in rats. J. Clin. Invest. 61:89.
11. Stuart, J. M., M. A. Cremer, A. H. Kang, and A. S. Townes. 1979. Collagen-induced arthritis in rats: evaluation of early immunologic events. Arthritis Rheum. 22:1344.
12. Dynesius-Trentham, R. A., D. Rowland, E. LaRoche, and D. E. Trentham. 1981. Rat leukocyte inhibitory factor (LIF): similarities to human LIF and generation by cells from rats with collagen-induced arthritis. Cell. Immunol. 63:362.
13. Trentham, D. E., W. J. McCune, P. Susman, and J. R. David. 1980. Autoimmunity to collagen in adjuvant arthritis of rats. J. Clin. Invest. 66:1109.
14. Ofosu-Appiah, W. A., K. Morgan, and P. J. Lennox Holt. 1983. Native type II collagen-induced arthritis in the rat. III. Relationship between the cellular immune response to native type II collagen and arthritis. Ann. Rheum. Dis. 42:351.
15. Brahn, E., and D. E. Trentham. 1984. Antigen-specific suppression of collagen arthritis by adoptive transfer of spleen cells. Clin. Immunol. Immunopathol. 31:124.
16. Schoen, R. T., H. Mehlman, D. E. Trentham, L. Perry, M. I. Greene, and J. R. David. 1981. Autoimmunity induced by type II collagen-coupled spleen cells. J. Immunol. 127:2275.
17. Dayer, J.-M., D. E. Trentham, and S. M. Krane. 1982. Collagens act as ligands to stimulate human monocytes to produce mononuclear cell factor (MCF) and prostaglandins (PGEs). Collagen Relat. Res. 2:523.
18. Brahn, E., and D. E. Trentham. 1984. Effect of antithymocyte serum on collagen arthritis in rats: evidence that T cells are involved in its pathogenesis. Cell. Immunol. 86:421.
19. Ben-Nun, A., H. Wekerle, and I. R. Cohen. 1981. The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis. Eur. J. Immunol. 11:195.
20. Ben-Nun, A., and I. R. Cohen. 1982. Experimental autoimmune encephalomyelitis (EAE) mediated by T cell lines. I. Process of selection and characterization of the cells. J. Immunol. 129:303.
21. Ben-Nun, A., and Z. Lando. 1983. Detection of autoimmune cells proliferating to myelin basic protein and selection of T cell lines that mediate experimental autoimmune encephalitis (EAE) in mice. J. Immunol. 130:1205.
22. Travis, J., J. Bowen, D. Tewksbury, D. Johnson, and R. Pannell. 1976. Isolation of albumin from whole human plasma and fractionation of albumin-depleted plasma. Biochem. J. 157:301.
23. Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:248.
24. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.). 227:680.
25. Wray, W., T. Boulkas, V. P. Wray, and R. Hancock. 1981. Silver staining of proteins in polyacrylamide gels. Anal. Biochem. 118:197.
26. Trentham, D. E., and R. A. Dynesius-Trentham. 1983. Attenuation of an adjuvant arthritis by type II collagen. J. Immunol. 130:2689.
27. Lowry, O. H., N. J. Rosebrough, A. L. Farr, and R. J. Randall. 1951. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:265.
28. Caulfield, J. P., A. Hein, R. Dynesius-Trentham, and D. E. Trentham. 1982. Morphologic demonstration of two stages in the development of type II collagen-induced arthritis. Lab. Invest. 46:321.
29. Rogers, M. P., D. E. Trentham, W. J. McCune, B. I. Ginsberg, H. G. Rennke, P. Reich, and J. R. David. 1980. Effect of psychological stress on the induction of arthritis in rats. Arthritis Rheum. 23:1397.
30. Andreis, M., P. Stasny, and M. Ziff. 1974. Experimental arthritis produced by injection of mediators of delayed hypersensitivity. Arthritis Rheum. 17:537.
31. Salant, D. J., S. Belok, M. P. Madaio, and W. G. Couser. 1980. A new role for complement in experimental membranous nephropathy in rats. J. Clin. Invest. 66:1339.
32. Cochrane, C. G., H. J. Müller-Eberhard, and B. S. Akin. 1970. Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions. J. Immunol. 105:55.
33. Mancini, O., A. O. Carbonara, and J. R. Heremans. 1965. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry. 2:235.
34. Fresno, M., L. McVay-Boudreau, G. Nabel, and H. Cantor. 1981. Antigen-specific T lymphocyte clones. II. Purification and biological characterization of an antigen-specific suppressive protein synthesized by cloned T cells. J. Exp. Med. 153:1260.
35. Beaman, K. D., N. H. Ruddle, A. L. M. Bothwell, and R. E. Cone. 1984. Messenger RNA for an antigen-specific binding molecule from an antigen-specific T cell hybrid. Proc. Natl. Acad. Sci. USA. 81:1524.
36. Askenase, P. W., R. W. Rosenstein, and W. Ptak. 1983. T cells produce an antigen-binding factor with in vivo activity analogous to IgE antibody. J. Exp. Med. 157:862.
37. James, R. F. L., S. Kontiainen, D. J. Maudsley, E. J. Culbert, and M. Feldman. 1983. A monoclonal antibody against antigen-specific helper factor augments T cell help. Nature (Lond.). 301:160.
38. Guy, R., and S. Z. Ben-Sasson. 1984. Antigen-specific helper factor production by immortalized clone of OVA-specific T cells. Cell. Immunol. 89:186.
39. Glomber, L. H., J. A. Schroer, C. Chan, and E. M. Shevach. 1983. Fine specificity of cloned insulin-specific T cell hybridomas: evidence supporting a role for tertiary conformation. J. Immunol. 131:2868.
40. Saklatvala, J., and J. Sarsfield. 1982. Lymphocytes induce resorption of cartilage by producing catabolins. Biochem. J. 202:275.
41. Krakauer, T., J. J. Oppenheim, and H. E. Jasin. 1983. Human interleukin 1 mediates cartilage matrix degradation. Cell. Immunol. 91:92.
42. Englert, M. R. A. McReynolds, M. J. Landes, A. L. Oronsky, and S. S. Kerwar. 1985. Pretreatment of rats with anticollagen IgG renders them resistant to active type II collagen arthritis. Cell. Immunol. 90:258.
43. Stasny, P., M. Rosenthal, M. Andreis, D. Cooke, and M. Ziff. 1975. Lymphokines in rheumatoid synovitis. Ann. N.Y. Acad. Sci. 256:117.
44. Trentham, D. E., R. A. Dynesius, R. E. Rocklin, and J. R. David. 1978. Cellular sensitivity to collagen in rheumatoid arthritis. N. Engl. J. Med. 299:327.
45. Stuart, J. M., A. E. Postlethwaite, A. H. Kang, and A. S. Townes. 1980. Cell-mediated immunity to collagen in rheumatoid arthritis and other rheumatic diseases. *Am. J. Med.* 69:13.

46. Klareskog, L., U. Forsum, A. Scheu, A. Kabelitz, and H. Wigzell. 1982. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. *Proc. Natl. Acad. Sci. USA.* 79:3632.

47. Gross, A., S. Frankenburg, and M. V. Londner. 1984. Cell-mediated immunity in rats injected with an antimalarial T cell line. *Cell. Immunol.* 84:14.

48. Zanetti, M., A. Altman, K. Evans, and J. Rogers. 1984. Autoreactive rat T cell lines: establishment and cellular characteristics. *Cell. Immunol.* 84:341.